Chlorpheniramine maleate; codeine phosphate - Generic Drug Details

What are the generic drug sources for chlorpheniramine maleate; codeine phosphate and what is the scope of patent protection?

Chlorpheniramine maleate; codeine phosphate is the generic ingredient in one branded drug marketed by Mainpointe and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for chlorpheniramine maleate; codeine phosphate

US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for chlorpheniramine maleate; codeine phosphate
DailyMed Link:	chlorpheniramine maleate; codeine phosphate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for chlorpheniramine maleate; codeine phosphate

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for chlorpheniramine maleate; codeine phosphate

Drug Class	Histamine-1 Receptor Antagonist Opioid Agonist
Mechanism of Action	Full Opioid Agonists Histamine H1 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for chlorpheniramine maleate; codeine phosphate

D04AA	Antihistamines for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

R06AB	Substituted alkylamines
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

US Patents and Regulatory Information for chlorpheniramine maleate; codeine phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mainpointe	TUXARIN ER	chlorpheniramine maleate; codeine phosphate	TABLET, EXTENDED RELEASE;ORAL	206323-001	Jun 22, 2015		RX	No	No
Mainpointe	TUXARIN ER	chlorpheniramine maleate; codeine phosphate	TABLET, EXTENDED RELEASE;ORAL	206323-001	Jun 22, 2015		RX	No	No			Y

Expired US Patents for chlorpheniramine maleate; codeine phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mainpointe	TUXARIN ER	chlorpheniramine maleate; codeine phosphate	TABLET, EXTENDED RELEASE;ORAL	206323-001	Jun 22, 2015
Mainpointe	TUXARIN ER	chlorpheniramine maleate; codeine phosphate	TABLET, EXTENDED RELEASE;ORAL	206323-001	Jun 22, 2015

Market Dynamics and Financial Trajectory for Chlorpheniramine Maleate and Codeine Phosphate

Last updated: February 13, 2026

Overview of Market Landscape

Chlorpheniramine maleate and codeine phosphate are combination ingredients primarily used in antitussive and antihistamine medications. Their market considers factors such as patent status, regulatory restrictions, consumer demand, and manufacturing costs.

Product Profile and Usage

• Chlorpheniramine maleate: An antihistamine used to treat allergy symptoms, hay fever, and cold symptoms.
• Codeine phosphate: An opioid used for cough suppression, pain relief, and as part of combination cold remedies.

Market Size and Growth Drivers

Global demand hinges on cold and allergy medication consumption. The market has historically expanded at a compound annual growth rate (CAGR) of approximately 3.5%. North America accounts for about 40% of the market, followed by Europe with 25%, and Asia-Pacific with 20% (Some estimates based on IQVIA data). The remaining 15% originates from Latin America and Africa.

Key Factors Driving Growth

• Rising prevalence of allergies and respiratory infections.
• Increased demand for combination cold remedies.
• Growing aging population with higher medication needs.
• Expanded distribution channels, including online pharmacies.

Regulatory Environment and Impact

Stringent regulations on opioids restrict access to formulations containing codeine in multiple markets.

• United States: The Drug Enforcement Administration (DEA) classifies combination products with codeine as Schedule III or V, restricting prescribing and dispensing.
• European Union: License restrictions limit over-the-counter availability in several countries.
• Asia: Regulatory pathways vary, with some countries imposing high taxes or outright bans on codeine-containing products.

Regulatory constraints influence supply, price stabilization, and market entry barriers.

Patent Expiry and Generic Competition

Most formulations containing chlorpheniramine maleate and codeine phosphate face imminent or recent patent expirations, encouraging generic competition. Generics generally hold 70-80% of the market in mature regions, exerting downward pressure on prices.

Pricing Trends

Prices vary by region, formulation, and regulatory status:

• North America: Brand products average $8–$15 per pack; generics sell at $4–$8.
• Europe: Similar price differentiation, averaging €5–€12.
• Asia-Pacific: Prices are lower—$2–$6 per pack—due to cost competition.

Revenue Projections and Financial Trajectory

Based on current demand and market trends:

Projection Year	Estimated Global Market Size (USD)	Growth Rate	Notes
2023	$1.2 billion	3.5% CAGR	Market maturity in developed regions
2025	$1.32 billion	3.5% CAGR	Increased generic penetration
2030	$1.55 billion	3.2% CAGR	Market saturation in mature regions

The CAGR is expected to decline slightly as the market matures. Growth will likely shift toward emerging markets with expanding healthcare access.

Market Challenges

• Regulatory Restrictions: Limiting sales in multiple jurisdictions.
• Antibiotic Resistance & Opioid Regulations: Stricter controls on codeine diminish availability.
• Market Saturation: Predominant use of generics constrains margins.
• Public Health Policies: A push to reduce opioid use affects codeine formulations.

Opportunities and Strategic Considerations

• Development of non-controlled, alternative formulations.
• Increased marketing in regions with lax regulations.
• Incorporation into combination therapies targeting severe allergies and coughs.
• Diversification into alternative delivery systems (e.g., patches, liquids).

Key Takeaways

• The market for chlorpheniramine maleate and codeine phosphate is stable but approaching maturity.
• Growth largely depends on emerging markets and new formulations.
• Regulatory restrictions on opioids restrain potential expansion.
• Generic competition keeps prices low, reducing profit margins for brand-name products.
• Innovation in delivery methods and alternative compounds may influence future revenue streams.

Frequently Asked Questions

1. How do regulatory changes affect market growth for chlorpheniramine and codeine formulations?
Regulations restricting opioid sales significantly reduce market size and slow growth. Countries tightening controls for safety issues diminish availability, while regions with lax enforcement see continued sales.

2. What is the expected impact of patent expiries on market dynamics?
Patent expiries enable generic entrants, increasing market competition and reducing prices. This compresses profit margins for brand-name manufacturers but expands access.

3. Are there emerging markets with high growth potential?
Yes. India, China, and Southeast Asian countries exhibit higher growth potential due to increasing healthcare infrastructure and demand for over-the-counter cold and allergy medications.

4. How is the shift towards non-opioid alternatives influencing the market?
Growing awareness and regulation of opioids prompt manufacturers to develop non-controlled cough suppressants or antihistamines, potentially replacing codeine-based formulations in some applications.

5. What future innovation strategies could benefit companies in this space?
Focusing on novel formulations with lower regulatory exposure, over-the-counter availability, and improved delivery methods can provide competitive advantages.

---

Sources:

1. IQVIA Institute for Human Data Science. Global Medicine Market Data, 2022.
2. United States Drug Enforcement Administration. Medication Scheduling and Regulation, 2023.
3. European Medicines Agency. Market Authorization Policies, 2023.
4. World Health Organization. Generic Medicine Market Reports, 2022.
5. Pharma Intelligence. Cold and Allergy Market Analysis, 2022.